Journal ArticleDOI
Carbamazepine in manic-depressive illness: a new treatment.
TLDR
In this paper, the authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness.Abstract:
The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness. Seven of 9 manic patients had a partial to marked response; several also showed relapses when placebo was substituted and improvement when carbamazepine was reinstituted. Five of 13 depressed patients showed significant improvement in depression ratings; 3 additional patients experienced partial relapse when placebo was substituted. Carbamazepine might also have prophylactic as well as acute efficacy in patients with both phases of manic-depressive illness, including some patients who do not respond to lithium. Therapeutic effects were achieved with 600-1600 mg/day at blood levels of 8-12 microgram/ml with relatively few side effects. Carbamazepine may prove to be a useful additional treatment for affective illness.read more
Citations
More filters
Journal ArticleDOI
Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2)
TL;DR: Whereas psychopharmacologic intervention may be required to resolve an active episode of major depression and to prevent recurrences, psychotherapy may be equally important to lessen the burden of stress imposed by intense inner conflict and counterproductive defenses.
Journal ArticleDOI
Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.
Kenneth Blum,Eric R. Braverman,Jay M. Holder,Joel F. Lubar,Vincent J. Monastra,David Miller,Judith O. Lubar,Thomas J H Chen,David E. Comings +8 more
TL;DR: In order to explain the breakdown of the reward cascade due to both multiple genes and environmental stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under the rubric of a reward deficiency syndrome.
Journal ArticleDOI
What Is a “Mood Stabilizer”? An Evidence-Based Response
Mark S. Bauer,Landis Mitchner +1 more
TL;DR: The evidence supported a role for lithium as first-line agent for treatment of bipolar disorder when all four treatment roles are considered and highlights unmet needs and promising agents and provides a yardstick for evaluating new treatment strategies.
Journal ArticleDOI
Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striatopallido-thalamic function
Neal R. Swerdlow,George F. Koob +1 more
TL;DR: A neural model is described that parallels existing explanations for the etiology of several movement disorders, and may lead to testable inferences regarding the neural substrates of specific psychopathologies.
Journal ArticleDOI
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Robert M. A. Hirschfeld,Charles L. Bowden,Michael J. Gitlin,Paul E. Keck,Roy H. Perlis,Trisha Suppes,Michael E. Thase,Karen Dineen Wagner +7 more
TL;DR: This guideline is more than 5 years old and has not yet been updated to Ensure that it reflects current knowledge and practice, and can no longer be assumed to be current.
Related Papers (5)
Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
Charles L. Bowden,Andrew M. Brugger,Alan C. Swann,Joseph R. Calabrese,Philip G. Janicak,Frederick Petty,Steven C. Dilsaver,John M. Davis,A. John Rush,Joyce G. Small,Enrique S. Garza-Treviño,S.Craig Risch,Paul J. Goodnick,David D. Morris,V.S. Shu,Philip C. Johnson,M. Blake,Martin A Javors,Larry Ereshefsky,Terry McLeod,Arif M. Shoaib,Mark H. Johnson,Susan E. Kimmel,A. Wesley,R. Qualtiere,C. Trivedi,J. I. Javaid,Jeremy C. Peterson,Michael T. Lambert,Martin D. Zielinski,Paul J. Orsulak,L. Sharp,L. Akers,Marvin J. Miller,Jeffrey J. Kellams,G. Woodham,Alan Frazer +36 more